Ardent Health (ARDT) investor relations material

Technology and operational transformation

• Significant investments in AI and digital platforms, including Epic and partnerships like hellocare.ai, are expected to drive care transformation, improve margins, and enhance productivity over time.

• Virtual nursing, virtual sitting, and ambient listening technologies are being rolled out to reduce labor costs, improve documentation, and support clinical staff.

• Early results show improved productivity and satisfaction among clinicians, with plans to expand these technologies system-wide.

• Revenue cycle improvements are underway through partnerships with Ensemble Health and Epic, leveraging AI to reduce denial rates and days sales outstanding.

• Collaborative projects with payers and Epic aim to streamline claims adjudication and reduce administrative friction.

Financial outlook and headwinds

• The expiration of federal subsidies is expected to create a $35 million headwind, with cautious assumptions about disenrollment and coverage shifts.

• Enrollment trends vary by state, with New Mexico seeing a 20% increase due to aggressive state funding, while Oklahoma declined.

• Rural hospital funding remains uncertain, with potential benefits not yet included in guidance due to lack of clarity on distribution.

• A one-time $42 million AR write-down resulted from migrating to a new revenue recognition system, with no ongoing impact.

• Payer denials and professional fee expenses are projected as a $50 million year-over-year headwind, especially across managed products.

Growth strategy and partnerships

• The joint venture model with academic and nonprofit partners is a key differentiator, enabling market expansion and leveraging partner strengths.

• Selective and disciplined approach to new hospital growth, focusing on accretive opportunities and leveraging technology for operational improvements.

• Outpatient expansion is prioritized, with urgent care acquisitions yielding new patient inflows and follow-up services, and plans to grow ASC and imaging center presence.

• Preference for de novo ASC builds over acquisitions due to cost advantages, with accelerated CapEx planned for expansion.

• Collaboration with Ventas supports growth in select markets, with flexibility for on-campus developments.